TABLE 2

The metabolic data of the study groups

Baseline
After 16 weeks
PlaceboRosiglitazonePlaceboRosiglitazone
At fast
    Plasma glucose mmol/l7.7 ± 1.77.3 ± 2.08.1 ± 2.36.0 ± 1.1*
    A1C (%)7.1 ± 0.97.3 ± 0.97.3 ± 1.06.9 ± 0.6*
    Serum insulin (pmol/l)53 ± 2649 ± 3456 ± 3634 ± 17
    Serum FFAs (mmol/l)0.81 ± 0.290.73 ± 0.240.80 ± 0.250.67 ± 0.22
    Serum C-peptide (nmol/l)0.87 ± 0.310.82 ± 0.340.85 ± 0.380.69 ± 0.24
    Total cholesterol (mmol/l)4.7 ± 0.84.2 ± 0.74.7 ± 0.94.7 ± 0.9
    LDL (mmol/l)2.7 ± 0.72.3 ± 0.82.7 ± 0.72.8 ± 0.7
    HDL (mmol/l)1.2 ± 0.31.1 ± 0.21.2 ± 0.31.1 ± 0.2
    Triglycerides (mmol/l)1.9 ± 1.01.7 ± 0.81.8 ± 1.01.7 ± 1.2
During hyperinsulinemia
    Plasma glucose (mmol/l)5.24 ± 0.535.28 ± 0.425.36 ± 0.755.23 ± 0.36
    Serum insulin (pmol/l)439 ± 88440 ± 78441 ± 76405 ± 66
    Serum FFAs (mmol/l)0.16 ± 0.080.14 ± 0.060.15 ± 0.060.10 ± 0.06§
    Whole-body glucose uptake (M value) (μmol · kg−1 · min−1)11.5 ± 4.212.3 ± 6.012.0 ± 5.517.8 ± 6.8*
  • Data are means ± SD.

  • *

    * P < 0.0001,

  • P = 0.003,

  • P = 0.006,

  • §

    § P = 0.014 change in rosiglitazone group vs. change in placebo group.